원내감염 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Hospital-Acquired Infection Diagnostics Market is anticipated to grow at a CAGR of 9.1% from USD 8.62 billion in 2026 to USD 18.88 billion in 2035.

The hospital-acquired infection diagnostics market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance, the growing burden of healthcare-associated infections, and the imperative for rapid pathogen identification to support targeted therapy. The market's evolution is characterized by a paradigm shift from conventional culture-based methods toward integrated molecular diagnostics, automated microbiology workflows, and multiplex syndromic testing platforms. Healthcare systems are expanding diagnostic capabilities to identify pathogens earlier, distinguish resistant organisms, and support targeted antimicrobial therapy before complications progress, reducing reliance on empirical treatment. The convergence of molecular diagnostics, mass spectrometry, and digital surveillance systems is enabling faster, more comprehensive, and increasingly actionable infection detection. Hospitals are expanding infection surveillance programs because healthcare-associated infections continue affecting a substantial proportion of hospitalized patients, creating sustained demand for laboratory automation and molecular diagnostics. Regulatory agencies are strengthening infection prevention and reporting frameworks, encouraging healthcare facilities to adopt standardized diagnostic protocols and surveillance systems. The market is witnessing significant investment in multiplex molecular assays, point-of-care technologies, and AI-enabled laboratory workflows, positioning HAI diagnostics as a critical component of patient safety, antimicrobial stewardship, and hospital quality performance.

Market Drivers

• The growing burden of healthcare-associated infections represents the primary driver for the HAI diagnostics market. Hospital-acquired infections remain a persistent challenge because invasive medical procedures, intensive care admissions, and aging patient populations continue increasing infection susceptibility. Healthcare providers are expanding diagnostic capacity to reduce delays between clinical suspicion and pathogen confirmation. Conventional microbiology often requires extended incubation periods, creating pressure for rapid molecular technologies that shorten treatment initiation. Diagnostic manufacturers are developing multiplex assays capable of detecting multiple pathogens simultaneously. Faster diagnosis improves infection control decisions while supporting antimicrobial stewardship programs that reduce inappropriate antibiotic utilization, resulting in sustained growth in HAI diagnostic utilization. Escalating antimicrobial resistance is further accelerating market growth through demand for rapid resistance detection. Antimicrobial resistance increases the complexity of hospital infection management because resistant pathogens frequently require organism-specific therapeutic strategies. Healthcare institutions are adopting advanced diagnostic platforms that rapidly identify resistance markers alongside pathogen detection. Delayed identification limits therapeutic effectiveness and increases healthcare costs through prolonged hospitalization. Diagnostic innovation is expanding toward syndromic panels and resistance gene detection to support precision antimicrobial selection. Earlier identification improves patient outcomes while strengthening antimicrobial stewardship programs across healthcare systems. The expansion of infection prevention programs is increasing demand for surveillance and automated reporting. Healthcare quality frameworks increasingly emphasize infection prevention as a measurable performance indicator. Hospitals are strengthening surveillance infrastructure to comply with national reporting requirements and accreditation standards. Manual surveillance limits timely intervention during outbreaks, creating demand for automated laboratory reporting and integrated diagnostic systems. Diagnostic vendors are incorporating connectivity features that enable real-time reporting to infection prevention teams. The increasing adoption of rapid molecular diagnostics is improving clinical decision-making and laboratory efficiency. Clinical decision-making depends on timely laboratory confirmation because delayed treatment increases morbidity and healthcare expenditure. Healthcare laboratories are replacing single-target assays with multiplex molecular platforms capable of identifying numerous pathogens during one testing cycle.

Market Restraints

• High capital investment requirements for molecular diagnostic platforms and laboratory automation limit adoption among small and resource-constrained healthcare facilities. The significant financial commitment creates barriers for smaller institutions. Reimbursement variability across healthcare systems reduces financial incentives for hospitals to replace conventional microbiology workflows with advanced molecular diagnostics. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Skilled laboratory workforce shortages and complex validation requirements slow implementation of sophisticated diagnostic technologies despite increasing clinical demand. The shortage of trained personnel limits the scalability of advanced diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Infection Type Insights

• The technology landscape is characterized by the growing importance of integrated molecular diagnostics and automated microbiology workflows. Molecular diagnostics increasingly occupy a central role because healthcare providers require actionable results within clinically relevant timeframes. Laboratories are expanding PCR and multiplex testing capabilities to identify pathogens and resistance markers simultaneously. Conventional microbiology culture-based testing remains an essential reference method because it supports antimicrobial susceptibility assessment and epidemiological investigations. Immunoassays continue serving targeted applications where rapid screening and cost efficiency remain priorities. Mass spectrometry-based diagnostics are gaining adoption because microbial identification workflows require higher throughput and greater analytical precision. The segment analysis reveals that bloodstream infections generate significant diagnostic demand because delayed identification increases mortality risk and extends hospitalization. Hospitals are prioritizing rapid molecular assays and automated blood culture technologies to accelerate therapeutic decisions. Surgical site infections require precise pathogen characterization because post-operative complications increase healthcare utilization and readmission rates. Healthcare providers are strengthening surveillance programs for hospital-acquired pneumonia, ventilator-associated pneumonia, and catheter-associated urinary tract infections as intensive care utilization remains high. Clostridioides difficile infections continue requiring specialized testing approaches because antimicrobial exposure alters gastrointestinal microbiota and increases recurrence risk. Laboratory-based testing remains the dominant diagnostic approach because hospitals require comprehensive pathogen identification, susceptibility testing, and surveillance reporting. Demand is shifting toward automated laboratory systems as healthcare facilities seek faster turnaround times without compromising diagnostic quality. Point-of-care testing is expanding because critical care environments require immediate clinical information to guide treatment initiation. The integration of AI is becoming increasingly important because laboratory automation continues advancing as healthcare systems require faster interpretation of growing diagnostic volumes. AI is supporting image analysis, microbial identification, and laboratory workflow optimization to improve operational efficiency.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized microbiology, molecular testing, and automation providers. Roche maintains a strong position in infectious disease diagnostics because its molecular testing portfolio supports rapid pathogen detection across hospital and laboratory environments, leveraging its cobas platform to provide scalable PCR-based testing solutions that integrate with established laboratory workflows. Thermo Fisher Scientific differentiates itself through a broad life sciences and diagnostics portfolio that supports microbiology, molecular testing, and laboratory automation, benefiting from strong integration across instruments, reagents, and laboratory services. bioMerieux remains strategically important because microbiology and infectious disease diagnostics form the core of its business model, supporting hospital laboratories through culture-based systems, molecular diagnostics, and antimicrobial stewardship solutions. BD occupies a distinctive position because it combines specimen management, microbiology diagnostics, and laboratory automation technologies, with its BD Kiestra automation platform supporting standardized workflows that reduce manual intervention and improve throughput. Danaher participates in the market through its diagnostic businesses, including Beckman Coulter and Cepheid, benefiting from strong capabilities in molecular diagnostics, laboratory automation, and clinical workflow optimization. Abbott leverages expertise in diagnostics, laboratory systems, and point-of-care testing to address infectious disease detection requirements. Siemens Healthineers differentiates itself through integration of diagnostics, laboratory automation, and healthcare technology solutions. QIAGEN maintains strategic relevance because its molecular diagnostic technologies support rapid detection of infectious agents and antimicrobial resistance markers. Companies are pursuing product portfolio expansion through innovation in multiplex molecular assays, point-of-care technologies, and AI-enabled laboratory workflows. Strategic collaborations between diagnostic manufacturers and healthcare systems are increasing, driven by the need for infection surveillance and antimicrobial stewardship. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The hospital-acquired infection diagnostics market is positioned for sustained growth driven by the convergence of infection burden, antimicrobial resistance, and diagnostic innovation. The transition from conventional culture-based methods toward integrated molecular and automated platforms represents a fundamental shift in infection management. While challenges related to high costs, reimbursement variability, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with HAI diagnostics evolving into a critical component of patient safety and healthcare quality, supporting rapid pathogen identification, antimicrobial stewardship, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Hospital-Acquired Infection Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Hospital-Acquired Infection Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Epidemiology and Disease Burden Analysis
• 3.8 Incidence of Major Hospital-Acquired Infections
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Testing Volume Analysis
• 3.11 Antimicrobial Resistance and Diagnostic Demand Assessment
• 3.12 Clinical Diagnostic Pathway Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Molecular Diagnostics Innovation
• 6.3 Rapid Point-of-Care Testing Developments
• 6.4 Clinical Trial Analysis
• 6.5 Pipeline Analysis of Diagnostic Assays and Platforms
• 6.6 Artificial Intelligence and Machine Learning Integration
• 6.7 Digital Health Integration and Hospital Surveillance Systems
• 6.8 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Hospital-Acquired Infection Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Testing Methodology
• 8.3 Analysis by Biomarker and Pathogen Detection Approach
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Diagnostic Turnaround Time

9. Hospital-Acquired Infection Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Infection Type
  • 9.1.1 Bloodstream Infections (BSIs)
  • 9.1.2 Surgical Site Infections (SSIs)
  • 9.1.3 Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
  • 9.1.4 Catheter-Associated Urinary Tract Infections (CAUTIs)
  • 9.1.5 Clostridioides difficile Infections (CDI)
  • 9.1.6 Other Hospital-Acquired Infections
• 9.2 By Diagnostic Technology
  • 9.2.1 Molecular Diagnostics
  • 9.2.2 Immunoassays
  • 9.2.3 Microbiology Culture-Based Testing
  • 9.2.4 Mass Spectrometry-Based Diagnostics
  • 9.2.5 Other Diagnostic Technologies
• 9.3 By Test Type
  • 9.3.1 Laboratory-Based Testing
  • 9.3.2 Point-of-Care Testing
• 9.4 By Pathogen Type
  • 9.4.1 Bacterial Pathogens
  • 9.4.2 Viral Pathogens
  • 9.4.3 Fungal Pathogens
  • 9.4.4 Multidrug-Resistant Organisms (MDROs)
• 9.5 By Sample Type
  • 9.5.1 Blood
  • 9.5.2 Urine
  • 9.5.3 Respiratory Samples
  • 9.5.4 Wound and Tissue Samples
  • 9.5.5 Stool Samples
  • 9.5.6 Other Samples
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Clinical Laboratories
  • 9.6.3 Reference Laboratories
  • 9.6.4 Academic and Research Institutes

10. Hospital-Acquired Infection Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Hospital-Acquired Infection Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 Australia
• 11.12 Brazil
• 11.13 Saudi Arabia
• 11.14 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Thermo Fisher Scientific Inc.
• 13.3 bioMerieux SA
• 13.4 Becton, Dickinson and Company
• 13.5 Danaher Corporation
• 13.6 Abbott Laboratories
• 13.7 Siemens Healthineers AG
• 13.8 Qiagen N.V.
• 13.9 Bio-Rad Laboratories, Inc.
• 13.10 Hologic, Inc.
• 13.11 Bruker Corporation
• 13.12 Revvity, Inc.
• 13.13 Cepheid
• 13.14 Seegene Inc.
• 13.15 Werfen S.A.

14. Hospital-Acquired Infection Diagnostics Market Commercial Forecast Analysis

• 14.1 Molecular Diagnostic Assays
• 14.2 Bloodstream Infection Diagnostic Solutions
• 14.3 Antimicrobial Resistance Detection Assays
• 14.4 Syndromic Testing Panels
• 14.5 Microbiology Culture and Identification Systems
• 14.6 Point-of-Care Infection Diagnostics
• 14.7 Mass Spectrometry-Based Microbial Identification Platforms

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends